




RealRate

PHARMACEUTICAL 2020

Zymeworks Inc.
Rank 155 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Zymeworks Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zymeworks Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Zymeworks Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 157% points.

The company's Economic Capital Ratio, given in the ranking table, is -131%, being 172% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	311,830
Cost of Goods Sold	0
Intangible Assets	18,073
Liabilities, Current	82,552
Liabilities, Non-Current	6,623
Other Assets	27,202
Other Compr. Net Income	0
Other Expenses	116,086
Other Liabilities	33,349
Other Net Income	5,282
Property and Equipment	11,100
Research and Development	0
Revenues	29,544
Selling, General and Administrative Expense	64,177

Output Variable	Value in 1000 USD
Assets	368,205
Liabilities	122,524
Expenses	180,263
Stockholders Equity	245,681
Net Income	-145,437
Comprehensive Net Income	-145,437
Economic Capital Ratio	-131%